Symbols / INO $1.14 +0.88% Inovio Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
INO Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Fundamentals
Scroll to Statements
Market Cap 93.01M Enterprise Value 28.93M Income -84.95M Sales 65.34K Book/sh 0.35 Cash/sh 0.85
Dividend Yield — Payout 0.00% Employees 112 IPO — P/E — Forward P/E -1.97
PEG — P/S 1423.49 P/B 3.27 P/C — EV/EBITDA -0.34 EV/Sales 442.73
Quick Ratio 1.34 Current Ratio 1.40 Debt/Eq 38.88 LT Debt/Eq — EPS (ttm) -1.81 EPS next Y -0.58
EPS Growth — Revenue Growth -100.00% Earnings 2026-05-13 ROA -57.88% ROE -183.47% ROIC —
Gross Margin 0.00% Oper. Margin -1328.71% Profit Margin 0.00% Shs Outstand 81.59M Shs Float 68.80M Short Float 16.68%
Short Ratio 14.51 Short Interest — 52W High 2.98 52W Low 1.03 Beta 1.70 Avg Volume 1.62M
Volume 684.42K Target Price $6.97 Recom Buy Prev Close $1.13 Price $1.14 Change 0.88%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.97
Mean price target
2. Current target
$1.14
Latest analyst target
3. DCF / Fair value
$-8.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.14
Low
$1.80
High
$13.00
Mean
$6.97

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-14 reit Piper Sandler Overweight → Overweight $6
2025-08-14 reit HC Wainwright & Co. Neutral → Neutral $3
2025-07-09 init Piper Sandler — → Overweight $5
2025-05-14 reit RBC Capital Sector Perform → Sector Perform $5
2025-05-14 main Oppenheimer Outperform → Outperform $13
2025-03-19 main RBC Capital Sector Perform → Sector Perform $5
2025-03-19 reit HC Wainwright & Co. Neutral → Neutral $3
2025-01-13 main HC Wainwright & Co. Neutral → Neutral $3
2025-01-10 reit JMP Securities Market Outperform → Market Outperform $18
2024-11-18 main HC Wainwright & Co. Neutral → Neutral $5
2024-11-18 main Oppenheimer Outperform → Outperform $15
2024-11-15 main RBC Capital Sector Perform → Sector Perform $6
2024-08-12 main Oppenheimer Outperform → Outperform $33
2024-08-09 main RBC Capital Sector Perform → Sector Perform $8
2024-07-15 reit HC Wainwright & Co. Neutral → Neutral $15
2024-05-14 init Stephens & Co. — → Overweight $20
2024-03-08 main Oppenheimer Outperform → Outperform $40
2024-03-07 reit RBC Capital Sector Perform → Sector Perform $11
2024-01-25 up Oppenheimer Perform → Outperform $4
News
RSS: Latest INO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 SUMNER MICHAEL JOHN Officer — 4,292 — —
2026-02-26 KIES PETER D Chief Financial Officer — 15,644 — —
2026-02-26 WEINER DAVID B Director — 972 — —
2026-02-26 HUMEAU LAURENT M Officer — 12,376 — —
2026-02-26 SHEA JACQUELINE ELIZABETH Chief Executive Officer — 47,033 — —
2026-02-26 SUMNER MICHAEL JOHN Officer — 16,560 — —
2025-06-30 SUMNER MICHAEL JOHN Officer — 2,916 — —
2025-05-21 SHEPARD JAY P. Director — 2,167 — —
2025-05-21 ZOTH LOTA S Director — 2,167 — —
2025-05-21 YARNO WENDY L Director — 2,167 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.07
-69.99%
0.22
-73.83%
0.83
-91.89%
10.26
Operating Revenue
0.07
-69.99%
0.22
-73.83%
0.83
-91.89%
10.26
Operating Expense
86.89
-22.85%
112.62
-16.12%
134.26
-51.68%
277.84
Research And Development
54.21
-28.32%
75.62
-12.76%
86.68
-53.81%
187.65
Selling General And Administration
32.68
-11.67%
37.00
-22.25%
47.58
-47.24%
90.19
General And Administrative Expense
32.68
-11.67%
37.00
-22.25%
47.58
-47.24%
90.19
Other Gand A
32.68
-11.67%
37.00
-22.25%
47.58
-47.24%
90.19
Total Expenses
86.89
-22.85%
112.62
-16.12%
134.26
-51.68%
277.84
Operating Income
-86.82
+22.76%
-112.40
+15.76%
-133.43
+50.13%
-267.57
Total Operating Income As Reported
-86.82
+22.76%
-112.40
+21.91%
-143.94
+46.21%
-267.57
EBITDA
-81.96
+21.15%
-103.95
+20.28%
-130.39
+51.87%
-270.90
Normalized EBITDA
-83.57
+23.22%
-108.83
+13.44%
-125.73
+52.20%
-263.06
Reconciled Depreciation
2.99
-4.51%
3.13
-10.66%
3.50
-36.25%
5.50
EBIT
-84.95
+20.67%
-107.08
+20.03%
-133.89
+51.56%
-276.40
Total Unusual Items
1.61
-67.09%
4.89
+204.78%
-4.66
+40.57%
-7.85
Total Unusual Items Excluding Goodwill
1.61
-67.09%
4.89
+204.78%
-4.66
+40.57%
-7.85
Special Income Charges
—
0.00
+100.00%
-10.51
0.00
Impairment Of Capital Assets
—
0.00
-100.00%
10.51
0.00
Net Income
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Pretax Income
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.34%
-277.65
Net Non Operating Interest Income Expense
2.42
-47.26%
4.59
-33.59%
6.91
+95.87%
3.53
Interest Expense Non Operating
0.00
-100.00%
0.18
-85.46%
1.22
-2.49%
1.25
Net Interest Income
2.42
-47.26%
4.59
-33.59%
6.91
+95.87%
3.53
Interest Expense
0.00
-100.00%
0.18
-85.46%
1.22
-2.49%
1.25
Interest Income Non Operating
2.42
-49.23%
4.77
-41.39%
8.13
+70.08%
4.78
Interest Income
2.42
-49.23%
4.77
-41.39%
8.13
+70.08%
4.78
Other Income Expense
-0.54
-197.90%
0.56
+106.46%
-8.60
+36.79%
-13.61
Other Non Operating Income Expenses
-2.64
+16.50%
-3.16
+32.85%
-4.71
-22.01%
-3.86
Gain On Sale Of Security
1.61
-67.09%
4.89
-16.49%
5.85
+174.57%
-7.85
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Net Income From Continuing Operation Net Minority Interest
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Net Income From Continuing And Discontinued Operation
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Net Income Continuous Operations
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Minority Interests
—
—
—
0.00
Normalized Income
-86.55
+22.82%
-112.14
+14.04%
-130.45
+52.03%
-271.97
Net Income Common Stockholders
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Diluted EPS
-1.81
+54.18%
-3.95
+35.14%
-6.09
+56.62%
-14.04
Basic EPS
-1.81
+54.18%
-3.95
+35.14%
-6.09
+56.62%
-14.04
Basic Average Shares
46.89
+72.62%
27.16
+22.49%
22.17
+11.51%
19.89
Diluted Average Shares
46.89
+72.62%
27.16
+22.49%
22.17
+11.51%
19.89
Diluted NI Availto Com Stockholders
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Earnings From Equity Interest
0.49
+141.99%
-1.17
-250.87%
0.77
+140.70%
-1.90
Earnings From Equity Interest Net Of Tax
—
—
0.00
+100.00%
-2.17
Line Item Trend 2023-12-31
Total Assets
170.95
Current Assets
153.11
Cash Cash Equivalents And Short Term Investments
145.29
Cash And Cash Equivalents
14.31
Other Short Term Investments
130.98
Receivables
2.41
Accounts Receivable
2.41
Prepaid Assets
5.41
Restricted Cash
0.00
Other Current Assets
0.02
Total Non Current Assets
17.84
Net PPE
14.45
Gross PPE
35.30
Accumulated Depreciation
-20.85
Properties
0.00
Machinery Furniture Equipment
6.36
Other Properties
13.03
Leases
15.92
Goodwill And Other Intangible Assets
0.00
Goodwill
0.00
Other Intangible Assets
—
Investments And Advances
2.78
Long Term Equity Investment
2.78
Other Non Current Assets
0.61
Total Liabilities Net Minority Interest
53.60
Current Liabilities
42.57
Payables And Accrued Expenses
13.45
Payables
4.65
Accounts Payable
4.65
Current Accrued Expenses
8.80
Pensionand Other Post Retirement Benefit Plans Current
9.84
Current Debt And Capital Lease Obligation
19.18
Current Debt
16.77
Other Current Borrowings
16.77
Current Capital Lease Obligation
2.41
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.11
Total Non Current Liabilities Net Minority Interest
11.03
Long Term Debt And Capital Lease Obligation
11.03
Long Term Debt
—
Long Term Capital Lease Obligation
11.03
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
—
Non Current Deferred Taxes Liabilities
0.00
Other Non Current Liabilities
—
Stockholders Equity
117.35
Common Stock Equity
117.35
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
22.79
Ordinary Shares Number
22.79
Treasury Shares Number
0.00
Additional Paid In Capital
1,740.95
Retained Earnings
-1,622.97
Gains Losses Not Affecting Retained Earnings
-0.66
Other Equity Adjustments
-0.66
Total Equity Gross Minority Interest
117.35
Total Capitalization
117.35
Working Capital
110.54
Invested Capital
134.12
Total Debt
30.21
Net Debt
2.46
Capital Lease Obligations
13.44
Net Tangible Assets
117.35
Tangible Book Value
117.35
Duefrom Related Parties Current
2.41
Investmentsin Associatesat Cost
—
Investmentsin Subsidiariesat Cost
—
Preferred Shares Number
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-88.63
+14.84%
-104.08
+16.31%
-124.37
+42.48%
-216.22
Cash Flow From Continuing Operating Activities
-88.63
+14.84%
-104.08
+16.31%
-124.37
+42.48%
-216.22
Net Income From Continuing Operations
-84.95
+20.80%
-107.25
+20.62%
-135.12
+51.71%
-279.82
Depreciation Amortization Depletion
2.99
-4.51%
3.13
-10.66%
3.50
-36.25%
5.50
Depreciation
2.99
-4.51%
3.13
-6.79%
3.36
-32.83%
5.00
Amortization Cash Flow
—
0.00
-100.00%
0.15
-70.71%
0.50
Depreciation And Amortization
2.99
-4.51%
3.13
-10.66%
3.50
-36.25%
5.50
Amortization Of Intangibles
—
0.00
-100.00%
0.15
-70.71%
0.50
Other Non Cash Items
—
-0.36
-328.26%
0.16
-16.67%
0.19
Stock Based Compensation
3.76
-43.05%
6.60
-40.44%
11.07
-50.91%
22.56
Asset Impairment Charge
—
0.00
-100.00%
12.50
0.00
Deferred Tax
—
0.00
+100.00%
-0.03
0.00
Deferred Income Tax
—
0.00
+100.00%
-0.03
0.00
Operating Gains Losses
-0.09
-138.28%
0.24
-94.47%
4.35
-51.68%
9.00
Gain Loss On Investment Securities
0.40
+144.03%
-0.90
-118.79%
4.81
+19.25%
4.03
Unrealized Gain Loss On Investment Securities
-1.11
+46.33%
-2.08
+64.50%
-5.85
-174.57%
7.85
Net Foreign Currency Exchange Gain Loss
—
—
—
—
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.02
-107.06%
0.32
-70.41%
1.07
Change In Working Capital
-9.22
-245.93%
-2.66
+74.03%
-10.26
-151.73%
19.83
Change In Receivables
—
1.21
-87.08%
9.33
+351.82%
-3.71
Changes In Account Receivables
—
1.21
-87.08%
9.33
+351.82%
-3.71
Change In Prepaid Assets
1.11
-58.89%
2.69
-93.11%
39.02
+831.20%
-5.34
Change In Payables And Accrued Expense
-7.79
-104.04%
-3.82
+92.95%
-54.22
-264.92%
32.87
Change In Accrued Expense
-1.37
-299.15%
-0.34
+95.83%
-8.23
-3172.62%
0.27
Change In Payable
-6.42
-84.76%
-3.48
+92.44%
-45.99
-241.04%
32.61
Change In Account Payable
-6.42
-84.76%
-3.48
+92.44%
-45.99
-241.04%
32.61
Change In Other Working Capital
-2.50
-58.72%
-1.57
+22.15%
-2.02
+24.87%
-2.69
Change In Other Current Assets
-0.03
-184.37%
0.04
-50.59%
0.08
-89.39%
0.74
Change In Other Current Liabilities
—
-0.11
+95.54%
-2.45
-19.71%
-2.05
Investing Cash Flow
14.04
-86.51%
104.07
+19.13%
87.36
-20.29%
109.59
Cash Flow From Continuing Investing Activities
14.04
-86.51%
104.07
+19.13%
87.36
-20.29%
109.59
Net PPE Purchase And Sale
-0.29
+33.33%
-0.43
-107.26%
5.90
+708.61%
-0.97
Purchase Of PPE
-0.29
+41.44%
-0.49
-52.02%
-0.32
+66.89%
-0.97
Sale Of PPE
0.00
-100.00%
0.06
-99.05%
6.22
0.00
Capital Expenditure
-0.29
+41.44%
-0.49
-52.02%
-0.32
+66.89%
-0.97
Capital Expenditure Reported
—
—
—
—
Net Investment Purchase And Sale
14.33
-86.29%
104.50
+28.29%
81.46
-27.63%
112.56
Purchase Of Investment
-4.95
+90.86%
-54.14
+73.39%
-203.48
+18.13%
-248.53
Sale Of Investment
19.27
-87.85%
158.64
-44.32%
284.93
-21.09%
361.08
Net Business Purchase And Sale
—
—
0.00
+100.00%
-2.00
Purchase Of Business
—
—
0.00
+100.00%
-2.00
Gain Loss On Sale Of Business
—
—
—
0.00
Financing Cash Flow
53.05
+3.06%
51.48
+930.52%
5.00
-93.90%
81.84
Cash Flow From Continuing Financing Activities
53.05
+3.06%
51.48
+930.52%
5.00
-93.90%
81.84
Net Issuance Payments Of Debt
0.00
+100.00%
-16.41
0.00
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-16.41
0.00
—
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
0.00
+100.00%
-16.41
0.00
—
Net Short Term Debt Issuance
0.00
+100.00%
-16.41
0.00
—
Net Common Stock Issuance
34.91
-3.12%
36.03
+559.74%
5.46
-93.42%
82.96
Proceeds From Stock Option Exercised
18.25
-43.45%
32.28
0.00
-100.00%
0.28
Net Other Financing Charges
-0.11
+73.67%
-0.42
+9.83%
-0.47
+66.61%
-1.40
Changes In Cash
-21.54
-141.85%
51.47
+260.77%
-32.01
-29.15%
-24.79
Effect Of Exchange Rate Changes
0.00
-100.00%
0.03
+926.61%
-0.00
+84.66%
-0.03
Beginning Cash Position
65.81
+359.88%
14.31
-69.11%
46.33
-34.88%
71.14
End Cash Position
44.27
-32.73%
65.81
+359.88%
14.31
-69.11%
46.33
Free Cash Flow
-88.92
+14.97%
-104.56
+16.14%
-124.69
+42.59%
-217.18
Interest Paid Supplemental Data
0.00
-100.00%
0.53
-50.00%
1.07
+0.00%
1.07
Income Tax Paid Supplemental Data
—
—
—
1.07
Amortization Of Securities
-0.00
+99.86%
-1.69
+63.92%
-4.69
-254.86%
-1.32
Common Stock Issuance
34.91
-3.12%
36.03
+559.74%
5.46
-93.42%
82.96
Earnings Losses From Equity Investments
-0.49
-141.99%
1.17
+250.87%
-0.77
-119.83%
3.90
Issuance Of Capital Stock
34.91
-3.12%
36.03
+559.74%
5.46
-93.42%
82.96
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category